Grey A, Bolland MJ, Horne A, et al. - Among older postmenopausal women who were treated with zoledronate, both a single baseline 5mg dose and 5-yearly doses of 1mg and 2.5mg prevented bone loss at hip and spine for 8-10 years.

• This is a second open-label extension (years 5-10) of a 2y randomized, multidose, placebo-controlled, double-blinded trial.

• A total of 116 older women either continued observation without further treatment (zoledronate 5mg and placebo at baseline) or took repeat doses of 1mg or 2.5mg zoledronate (zoledronate 1mg and zoledronate 2.5mg at baseline, respectively).

• Maintenance of mean bone mineral density (BMD) at the lumbar spine and total hip at or above baseline levels for 9 and 10 years, respectively, was seen both after a single 5mg dose of zoledronate as well as after 5-yearly doses of 2.5mg zoledronate.

• Bone turnover markers decreased for 3-4 years as a result of redosing with 1mg or 2.5mg zoledronate at 5 years.

• An increase in BMD for 3-4 years happened following redosing with 1mg zoledronate.